Welcome to our dedicated page for KESTRA MED TECHNOLOGIES news (Ticker: KMTS), a resource for investors and traders seeking the latest updates and insights on KESTRA MED TECHNOLOGIES stock.
News for Kestra Medical Technologies, Ltd. (Nasdaq: KMTS) focuses on its activities as a commercial-stage wearable medical device and digital healthcare company in cardiovascular care. Company announcements highlight developments related to its Cardiac Recovery System platform and ASSURE Wearable Cardioverter Defibrillator (ASSURE WCD), as well as financial performance and capital markets activity.
Investors and clinicians following KMTS news will see updates on clinical evidence, including communications about the ASSURE WCD Clinical Evaluation Post-Approval Study (ACE-PAS), which Kestra describes as the largest prospective real-world study of wearable defibrillators to date. Press releases detail study design and key endpoints such as shock conversion success, inappropriate shock rates, wear time, and detection of additional arrhythmias in diverse cardiac recovery populations.
Kestra’s news flow also includes information on strategic collaborations, such as its agreement with Biobeat Technologies, Ltd. to integrate FDA-cleared, cuffless ambulatory blood pressure monitoring into the ASSURE WCD ecosystem. These items explain how additional diagnostic data, like 24-hour blood pressure measurements, may expand the clinical insights available for patients prescribed the wearable defibrillator.
Financial and corporate updates are another key component of KMTS coverage. The company issues press releases on quarterly financial results, preliminary revenue and margin trends, and public offerings of common shares. It also announces participation in major healthcare and investor conferences, including cardiology meetings and investment bank conferences, where management presents Kestra’s strategy and platform.
This news page aggregates these disclosures so readers can track Kestra’s clinical milestones, technology integrations, financial updates, and conference appearances in one place. For ongoing research into KMTS, users can review both operational announcements and regulatory communications as they are released.
Kestra Medical Technologies (Nasdaq: KMTS), a wearable medical device and digital healthcare company, has scheduled its third quarter fiscal 2025 financial results announcement for Monday, April 14. The company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time to discuss the results. Investors can access both live and archived versions of the webcast through the 'Events' section of the investor relations website, with registration recommended at least 10 minutes before the call.
Kestra Medical Technologies (KMTS), a wearable medical device and digital healthcare company, has announced the full exercise of the underwriters' over-allotment option in its Initial Public Offering (IPO). The underwriters purchased an additional 1,782,352 shares at $17.00 per share.
Following this over-allotment exercise, the total IPO size reached 13,664,704 shares, generating total gross proceeds of approximately $232 million before deducting underwriting discounts, commissions, and other offering expenses.
The offering's lead bookrunners were BofA Securities, Goldman Sachs & Co. , and Piper Sandler, with Wells Fargo Securities and Stifel acting as bookrunners, and Wolfe | Nomura Alliance as co-manager. The registration statement became effective on March 5, 2025.
Kestra Medical Technologies (Nasdaq: KMTS), a wearable medical device and digital healthcare company, has successfully completed its upsized initial public offering (IPO). The company offered 11,882,352 common shares at $17.00 per share, generating total gross proceeds of approximately $202 million before deducting underwriting discounts and other expenses.
Trading of Kestra's common shares commenced on the Nasdaq Global Select Market on March 6, 2025, under the ticker symbol 'KMTS'. The IPO was led by BofA Securities, Goldman Sachs & Co. , and Piper Sandler as lead bookrunners, with Wells Fargo Securities and Stifel acting as bookrunners and Wolfe | Nomura Alliance as co-manager.
Kestra Medical Technologies, a wearable medical device and digital healthcare company, has announced the pricing of its upsized IPO of 11,882,352 common shares at $17.00 per share. The shares will trade on the Nasdaq Global Select Market under the symbol 'KMTS' starting March 6, 2025.
The company expects to raise approximately $202 million in gross proceeds before deducting underwriting costs and other expenses. Underwriters have a 30-day option to purchase up to 1,782,352 additional shares at the IPO price. The offering is expected to close on March 7, 2025.
Lead bookrunners include BofA Securities, Goldman Sachs & Co. , and Piper Sandler, with Wells Fargo Securities and Stifel as bookrunners and Wolfe | Nomura Alliance as co-manager.
Kestra Medical Technologies, a wearable medical device and digital healthcare company, has announced the launch of its Initial Public Offering (IPO). The company plans to offer 10,000,000 common shares with an expected price range of $14.00 to $16.00 per share.
Underwriters will have a 30-day option to purchase up to 1,500,000 additional shares at the IPO price, less underwriting discounts and commissions. Kestra has applied to list on the Nasdaq Global Select Market under the symbol 'KMTS'.
The offering is led by BofA Securities, Goldman Sachs, and Piper Sandler as lead bookrunners, with Wells Fargo Securities and Stifel as bookrunners and Wolfe | Nomura Alliance as co-manager.